Dow Up0.17% Nasdaq Up0.03%

Cara Therapeutics Inc. (CARA)

10.17 Up 0.15(1.50%) 12:37PM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
Cara Therapeutics Inc.
1 Parrott Drive
Shelton, CT 06484
United States - Map
Phone: 203-567-1500
Fax: 203-567-1510

Index Membership:N/A
Full Time Employees:11

Business Summary 

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors. Its lead product candidate includes intravenous CR845, which has completed Phase II clinical trials for the treatment acute postoperative pain in adult patients. The company is also developing Oral CR845 that has completed Phase I clinical trial for the treatment of moderate-to-severe acute and chronic pain; and CR701, which is in preclinical trial for treating neuropathic and inflammatory pain. Cara Therapeutics, Inc. was founded in 2004 and is based in Shelton, Connecticut.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Cara Therapeutics Inc.

Key Executives 
Dr. Derek T. Chalmers Ph.D., D.Sc., 50
Co-Founder, Chief Exec. Officer, Pres and Director
Mr. Josef Schoell , 63
Chief Financial Officer and Principal Accounting Officer
Dr. Fr Menzaghi Ph.D., 48
VP of R&D
Dr. Michael E. Lewis Ph.D., 62
Chief Scientific Advisor
Dr. Robert Medve M.D.,
Chief Medical Officer
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders